IL124472A - תהליך וערכה למניעת הריון של יונק ממין נקבה אשר מכיל תערובת של גאסטאגן ואסטרוגן - Google Patents
תהליך וערכה למניעת הריון של יונק ממין נקבה אשר מכיל תערובת של גאסטאגן ואסטרוגןInfo
- Publication number
- IL124472A IL124472A IL12447296A IL12447296A IL124472A IL 124472 A IL124472 A IL 124472A IL 12447296 A IL12447296 A IL 12447296A IL 12447296 A IL12447296 A IL 12447296A IL 124472 A IL124472 A IL 124472A
- Authority
- IL
- Israel
- Prior art keywords
- gestagen
- days
- administration
- estrogen
- ovulation
- Prior art date
Links
- 239000000583 progesterone congener Substances 0.000 title claims abstract description 63
- 229940011871 estrogen Drugs 0.000 title claims abstract description 37
- 239000000262 estrogen Substances 0.000 title claims abstract description 37
- 239000003433 contraceptive agent Substances 0.000 title claims abstract description 22
- 230000002254 contraceptive effect Effects 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title claims abstract description 19
- 230000008569 process Effects 0.000 title claims abstract description 18
- 241000124008 Mammalia Species 0.000 title claims abstract description 7
- 230000016087 ovulation Effects 0.000 claims abstract description 17
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 13
- 229960004400 levonorgestrel Drugs 0.000 claims description 14
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 13
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 claims description 12
- 229960005352 gestodene Drugs 0.000 claims description 12
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 claims description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 6
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 claims description 6
- 229960004845 drospirenone Drugs 0.000 claims description 6
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 claims description 6
- 229960004976 desogestrel Drugs 0.000 claims description 5
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 claims description 5
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 229940053934 norethindrone Drugs 0.000 claims description 4
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 4
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 claims description 3
- 229960000978 cyproterone acetate Drugs 0.000 claims description 3
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 claims description 3
- 229960003309 dienogest Drugs 0.000 claims description 3
- 229960001652 norethindrone acetate Drugs 0.000 claims description 3
- 229960000417 norgestimate Drugs 0.000 claims description 3
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 claims description 3
- 229960003387 progesterone Drugs 0.000 claims description 3
- 239000000186 progesterone Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 description 29
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 13
- 229960005309 estradiol Drugs 0.000 description 13
- 229930182833 estradiol Natural products 0.000 description 13
- 230000000740 bleeding effect Effects 0.000 description 7
- 230000003054 hormonal effect Effects 0.000 description 7
- 210000004696 endometrium Anatomy 0.000 description 4
- 229940062161 gestodene 0.075 mg Drugs 0.000 description 4
- 229940096541 levonorgestrel 0.1 mg Drugs 0.000 description 4
- 229940124558 contraceptive agent Drugs 0.000 description 3
- 239000007933 dermal patch Substances 0.000 description 3
- 239000003539 oral contraceptive agent Substances 0.000 description 3
- 206010047998 Withdrawal bleed Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 229940127234 oral contraceptive Drugs 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000006213 vaginal ring Substances 0.000 description 2
- 150000000319 19-nortestosterones Chemical class 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002659 Anovulatory cycle Diseases 0.000 description 1
- 241000252095 Congridae Species 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 231100000546 inhibition of ovulation Toxicity 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 229960001910 lynestrenol Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000003408 postcoitus contraceptive agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940100640 transdermal system Drugs 0.000 description 1
- 239000000029 vaginal gel Substances 0.000 description 1
- 229940044953 vaginal ring Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19549264A DE19549264A1 (de) | 1995-12-23 | 1995-12-23 | Verfahren und Kit zur Kontrazeption |
| PCT/DE1996/002486 WO1997023228A2 (de) | 1995-12-23 | 1996-12-20 | Verfahren und kit zur kontrazeption bei weiblichen säugern, bestehend aus einer kombination von gestagen und estrogen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL124472A0 IL124472A0 (en) | 1998-12-06 |
| IL124472A true IL124472A (he) | 2001-07-24 |
Family
ID=7781724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12447296A IL124472A (he) | 1995-12-23 | 1996-12-20 | תהליך וערכה למניעת הריון של יונק ממין נקבה אשר מכיל תערובת של גאסטאגן ואסטרוגן |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6995149B1 (he) |
| EP (1) | EP0868188B1 (he) |
| JP (1) | JP2000502108A (he) |
| KR (1) | KR19990076685A (he) |
| AT (1) | ATE244567T1 (he) |
| AU (1) | AU716249B2 (he) |
| BR (1) | BR9612207A (he) |
| CA (1) | CA2241192A1 (he) |
| CZ (1) | CZ291743B6 (he) |
| DE (2) | DE19549264A1 (he) |
| DK (1) | DK0868188T3 (he) |
| ES (1) | ES2202498T3 (he) |
| HU (1) | HUP9901662A3 (he) |
| IL (1) | IL124472A (he) |
| IS (1) | IS4753A (he) |
| MX (1) | MX9804395A (he) |
| NO (1) | NO982902D0 (he) |
| NZ (1) | NZ330741A (he) |
| PL (1) | PL187180B1 (he) |
| PT (1) | PT868188E (he) |
| SK (1) | SK79298A3 (he) |
| UA (1) | UA59356C2 (he) |
| WO (1) | WO1997023228A2 (he) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001030355A1 (fr) | 1999-10-25 | 2001-05-03 | Laboratoire Theramex | Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation |
| FR2754179B1 (fr) * | 1996-10-08 | 1998-12-24 | Theramex | Nouvelle composition hormononale et son utilisation |
| JP2001516720A (ja) * | 1997-09-12 | 2001-10-02 | アメリカン・ホーム・プロダクツ・コーポレイション | プロゲスチン／エストロゲンからなる第一相とプロゲスチンからなる第二相とを有する経口避妊薬製剤 |
| EP1535618A1 (en) * | 2003-11-26 | 2005-06-01 | Schering Aktiengesellschaft | Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions |
| DE102008036825A1 (de) * | 2008-08-05 | 2010-02-11 | Aicuris Gmbh & Co. Kg | Schwangerschaftsvermeidung durch Gestagene |
| EP2343963B1 (en) | 2008-10-08 | 2019-04-10 | Agile Therapeutics, Inc. | Transdermal delivery |
| CA2740004A1 (en) * | 2008-10-08 | 2010-04-15 | Agile Therapeutics, Inc. | Transdermal delivery |
| WO2010042612A1 (en) * | 2008-10-08 | 2010-04-15 | Agile Therapeutics, Inc. | Transdermal delivery |
| EP2410859A4 (en) * | 2009-03-27 | 2013-03-13 | Agile Therapeutics Inc | TRANSDERMAL ADMINISTRATION |
| US9629895B2 (en) * | 2011-01-12 | 2017-04-25 | University Of Miyazaki | Method for prevention or treatment of intractable inflammatory bowel disease |
| WO2013078422A2 (en) | 2011-11-23 | 2013-05-30 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0368373A1 (en) | 1988-10-13 | 1990-05-16 | Akzo Nobel N.V. | Multi-phase contraceptive preparation |
| NL9301562A (nl) * | 1993-09-09 | 1995-04-03 | Saturnus Ag | Preparaat voor substitutietherapie. |
| HU228434B1 (en) * | 1995-06-07 | 2013-03-28 | Ortho Mcneil Pharm Inc | Transdermal medicament for administering 17-deacetyl norgestimate alone or in combination with an estrogen |
| US5770226A (en) * | 1996-07-10 | 1998-06-23 | Wake Forest University | Combined pharmaceutical estrogen-androgen-progestin oral contraceptive |
| US6139873A (en) * | 1996-07-10 | 2000-10-31 | Cedars-Sinai Medical Center | Combined pharmaceutical estrogen-androgen-progestin |
| US5888543A (en) * | 1996-07-26 | 1999-03-30 | American Home Products Corporation | Oral contraceptives |
| US6479475B1 (en) * | 1996-07-26 | 2002-11-12 | Wyeth | Oral contraceptive |
| FR2754179B1 (fr) * | 1996-10-08 | 1998-12-24 | Theramex | Nouvelle composition hormononale et son utilisation |
| US5898032A (en) * | 1997-06-23 | 1999-04-27 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
| WO2000009658A2 (en) * | 1998-08-17 | 2000-02-24 | The State University Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Gene regulating circadian clock function and photoperiodism |
-
1995
- 1995-12-23 DE DE19549264A patent/DE19549264A1/de not_active Withdrawn
-
1996
- 1996-12-20 CA CA002241192A patent/CA2241192A1/en not_active Abandoned
- 1996-12-20 WO PCT/DE1996/002486 patent/WO1997023228A2/de not_active Application Discontinuation
- 1996-12-20 ES ES96946221T patent/ES2202498T3/es not_active Expired - Lifetime
- 1996-12-20 CZ CZ19982000A patent/CZ291743B6/cs not_active IP Right Cessation
- 1996-12-20 SK SK792-98A patent/SK79298A3/sk unknown
- 1996-12-20 AT AT96946221T patent/ATE244567T1/de not_active IP Right Cessation
- 1996-12-20 KR KR1019980704797A patent/KR19990076685A/ko not_active Application Discontinuation
- 1996-12-20 DE DE59610600T patent/DE59610600D1/de not_active Expired - Lifetime
- 1996-12-20 JP JP9523223A patent/JP2000502108A/ja active Pending
- 1996-12-20 HU HU9901662A patent/HUP9901662A3/hu unknown
- 1996-12-20 BR BR9612207A patent/BR9612207A/pt not_active Application Discontinuation
- 1996-12-20 DK DK96946221T patent/DK0868188T3/da active
- 1996-12-20 PL PL96327182A patent/PL187180B1/pl not_active IP Right Cessation
- 1996-12-20 EP EP96946221A patent/EP0868188B1/de not_active Expired - Lifetime
- 1996-12-20 US US09/091,665 patent/US6995149B1/en not_active Expired - Fee Related
- 1996-12-20 AU AU19219/97A patent/AU716249B2/en not_active Ceased
- 1996-12-20 NZ NZ330741A patent/NZ330741A/xx unknown
- 1996-12-20 UA UA98074032A patent/UA59356C2/uk unknown
- 1996-12-20 IL IL12447296A patent/IL124472A/he not_active IP Right Cessation
- 1996-12-20 PT PT96946221T patent/PT868188E/pt unknown
-
1998
- 1998-05-22 IS IS4753A patent/IS4753A/is unknown
- 1998-06-03 MX MX9804395A patent/MX9804395A/es not_active IP Right Cessation
- 1998-06-22 NO NO982902A patent/NO982902D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000502108A (ja) | 2000-02-22 |
| HUP9901662A3 (en) | 1999-11-29 |
| WO1997023228A2 (de) | 1997-07-03 |
| PT868188E (pt) | 2003-11-28 |
| EP0868188B1 (de) | 2003-07-09 |
| UA59356C2 (uk) | 2003-09-15 |
| NO982902L (no) | 1998-06-22 |
| NZ330741A (en) | 2000-03-27 |
| HUP9901662A2 (hu) | 1999-09-28 |
| EP0868188A2 (de) | 1998-10-07 |
| CZ291743B6 (cs) | 2003-05-14 |
| MX9804395A (es) | 1998-09-30 |
| AU1921997A (en) | 1997-07-17 |
| IL124472A0 (en) | 1998-12-06 |
| DE59610600D1 (de) | 2003-08-14 |
| KR19990076685A (ko) | 1999-10-15 |
| ES2202498T3 (es) | 2004-04-01 |
| CZ9802000A3 (cs) | 1998-11-11 |
| CA2241192A1 (en) | 1997-07-03 |
| IS4753A (is) | 1998-05-22 |
| PL327182A1 (en) | 1998-11-23 |
| ATE244567T1 (de) | 2003-07-15 |
| NO982902D0 (no) | 1998-06-22 |
| BR9612207A (pt) | 1999-07-13 |
| US6995149B1 (en) | 2006-02-07 |
| PL187180B1 (pl) | 2004-05-31 |
| WO1997023228A3 (de) | 1997-08-28 |
| DE19549264A1 (de) | 1997-06-26 |
| AU716249B2 (en) | 2000-02-24 |
| DK0868188T3 (da) | 2003-10-06 |
| SK79298A3 (en) | 2000-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU716249B2 (en) | Contraceptive process and kit for female mammals that consists of a combination of gestagen and estrogen | |
| US4628051A (en) | Triphasic oral contraceptive | |
| US4544554A (en) | Triphasic oral contraceptive | |
| JP3020880B2 (ja) | 避妊のための多段階調剤 | |
| US4616006A (en) | Triphasic oral contraceptive | |
| US4530839A (en) | Triphasic oral contraceptive | |
| CA2609336C (en) | Quadraphasic continuous graduated estrogen contraceptive | |
| US5756490A (en) | Pharmaceutical combination preparation for hormonal contraception | |
| EP0912186B1 (en) | Progestogen-anti-progestogen regimens | |
| AU726091B2 (en) | Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen | |
| CZ420597A3 (cs) | Farmaceutický kombinovaný preparát, souprava a způsob pro hormonální antikoncepci | |
| US6506390B2 (en) | Progestogen-anti-progestogen regimens | |
| KR19980703702A (ko) | 호르몬 피임법용 제약학상 복합 제제 | |
| JP2000515888A (ja) | 経口避妊薬 | |
| AU759925B2 (en) | Oral contraceptive preparation having a first phase comprising progestin/estrogen and a second phase comprising progestin | |
| US6642219B1 (en) | Progestogen-antiprogestogen regimens | |
| JP2000515889A (ja) | プロゲスチンとエストロゲンとの混合剤からなる二相性避妊法およびキット | |
| WO2021260511A1 (en) | Multiphasic contraceptive and/or hormone replacement therapy | |
| WO1999051214A2 (en) | Progestogen-only contraceptive kit | |
| MXPA00004610A (en) | Progestogen-antiprogestogen regimens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |